Drug Trial Radar · NCT05948774
A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jul 11, 2023
Primary completion
Jan 22, 2024
Study completion Feb 11, 2024
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this randomized, double-blind, placebo control, Phase I clinical trial is to evaluate the Safety, Tolerability, and Pharmacokinetics after Single Ascending Dose (SAD) and multiple Ascending Dose (MAD) of MT200605 for Injection in Healthy Subjects. The main questions it aims to answer are: 1. The safety and tolerability of MT200605 injection in health subjects 2. The Pharmacokinetic characteristic of MT200605 injction in health subjects The study aims to recruit 60 health subjects and participants will be randomly allocate to two stages (SAD and MAD) with 36 subjects in SAD and 24 subjects in MAD stages. The placebo will be used in this study, and the researchers will compare the placebo and test article to see if the MT200605 will be safe or well tolerated.
Conditions
- Healthy
Interventions
MT200605 for InjectionDrug
Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
MT200605 PlaceboDrug
Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events(AEs)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
- Adverse Events(AEs)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
- Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
- Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks.
- Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Vital signs (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Vital signs (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- 12-lead electrocardiogram (ECG) recordings (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Head (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Eyes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Ears (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Nose (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-throat (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-neck (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-lung (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Abdomen (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-skin (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Musculoskeletal (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Cardiovascular (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-neurological (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-lung (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Abdomen (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-skin (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Physical examinations-Cardiovascular (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-biochemistry (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-biochemistry (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Urinalysis (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Cardiac Enzymes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Cardiac Enzymes (SAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-hematology (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-biochemistry (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-biochemistry (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Urinalysis (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Coagulation (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Cardiac Enzymes (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
- Clinical laboratory test-Cardiac Enzymes (MAD)Time frame: From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.